[go: up one dir, main page]

PE20230998A1 - Receptores de union al antigeno mejorada - Google Patents

Receptores de union al antigeno mejorada

Info

Publication number
PE20230998A1
PE20230998A1 PE2023000202A PE2023000202A PE20230998A1 PE 20230998 A1 PE20230998 A1 PE 20230998A1 PE 2023000202 A PE2023000202 A PE 2023000202A PE 2023000202 A PE2023000202 A PE 2023000202A PE 20230998 A1 PE20230998 A1 PE 20230998A1
Authority
PE
Peru
Prior art keywords
seq
antigen
lcdr
hcdr
antigen binding
Prior art date
Application number
PE2023000202A
Other languages
English (en)
Inventor
Diana Darowski
Anne Freimoser-Grundschober
Christian Klein
Ekkehard Moessner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20230998A1 publication Critical patent/PE20230998A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/33—Antibodies; T-cell engagers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4221—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/21—Transmembrane domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/22—Intracellular domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)

Abstract

Referido a receptores de union al antigeno mejorada que comprende un dominio transmembranario de anclaje y un dominio extracelular, en donde el dominio extracelular comprende una porcion de union al antigeno que comprende (i) un dominio variable de la cadena pesada (VH) que comprende una region determinante de la complementariedad de la cadena pesada (HCDR) 1 de SEQ ID NO:1, una HCDR 2 de SEQ ID NO:2 o SEQ ID NO:40, y una HCDR 3 de SEQ ID NO:3, y (ii) un dominio variable de la cadena liviana (VL) que comprende una region determinante de la complementariedad de la cadena liviana (LCDR) 1 de SEQ ID NO:4, una LCDR 2 de SEQ ID NO:5 y una LCDR 3 de SEQ ID NO:6. Tambien se refiere a un linfocito T transducido capaz de expresar el receptor de union al antigeno, un polinucleotido aislado que codifica el receptor de union al antigeno, un vector de expresion, y uso en el tratamiento del cancer.
PE2023000202A 2020-08-03 2021-08-02 Receptores de union al antigeno mejorada PE20230998A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20189196 2020-08-03
EP21158659 2021-02-23
PCT/EP2021/071515 WO2022029051A1 (en) 2020-08-03 2021-08-02 Improved antigen binding receptors

Publications (1)

Publication Number Publication Date
PE20230998A1 true PE20230998A1 (es) 2023-06-26

Family

ID=77411698

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023000202A PE20230998A1 (es) 2020-08-03 2021-08-02 Receptores de union al antigeno mejorada

Country Status (16)

Country Link
US (1) US20230322950A1 (es)
EP (1) EP4188964A1 (es)
JP (1) JP2023536169A (es)
KR (1) KR20230042292A (es)
CN (1) CN116234831A (es)
AU (1) AU2021322054A1 (es)
BR (1) BR112023001740A2 (es)
CA (1) CA3185687A1 (es)
CL (1) CL2023000351A1 (es)
CO (1) CO2023002334A2 (es)
CR (1) CR20230045A (es)
IL (1) IL298449A (es)
MX (1) MX2023001148A (es)
PE (1) PE20230998A1 (es)
TW (1) TW202221021A (es)
WO (1) WO2022029051A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
CN116162168A (zh) * 2021-11-25 2023-05-26 信达细胞制药(苏州)有限公司 分子开关调控型嵌合抗原受体细胞和抗体的组合及其应用
CN118252923A (zh) * 2022-12-28 2024-06-28 信达细胞制药(苏州)有限公司 靶向nkg2d配体的融合蛋白与嵌合抗原受体细胞的组合及其用途
CN118477173A (zh) * 2023-02-13 2024-08-13 信达细胞制药(苏州)有限公司 靶向HER2/p95HER2的P329G抗体及其与嵌合抗原受体细胞的组合和应用
WO2024251547A1 (en) 2023-06-06 2024-12-12 F. Hoffmann-La Roche Ag Switch receptors
WO2024251132A1 (zh) * 2023-06-06 2024-12-12 信达细胞制药(苏州)有限公司 一种包含bcma pg car-t细胞制剂和pg抗体制剂的药物组合制剂及其用途
WO2025040567A1 (en) 2023-08-18 2025-02-27 F. Hoffmann-La Roche Ag Protease activatable fc domain binding molecules

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
GB9304200D0 (en) 1993-03-02 1993-04-21 Sandoz Ltd Improvements in or relating to organic compounds
CA2164088C (en) 1993-06-07 2005-06-14 Gary J. Nabel Plasmids suitable for gene therapy
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU6117000A (en) 1999-07-26 2001-02-13 Genentech Inc. Novel polynucleotides and method of use thereof
BR122019012028B1 (pt) 2004-04-13 2023-09-26 F. Hoffmann-La Roche Ag Anticorpos anti-p-selectina, molécula de ácido nucléico, vetor, e composição
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
DK1871805T3 (da) 2005-02-07 2019-12-02 Roche Glycart Ag Antigenbindende molekyler der binder egfr, vektorer der koder derfor, og anvendelser deraf
SI2691417T1 (sl) 2011-03-29 2018-11-30 Roche Glycart Ag FC variante protitelesa
CN110662560B (zh) * 2017-03-27 2024-06-28 豪夫迈·罗氏有限公司 改进的抗原结合受体

Also Published As

Publication number Publication date
IL298449A (en) 2023-01-01
WO2022029051A1 (en) 2022-02-10
CA3185687A1 (en) 2022-02-10
CL2023000351A1 (es) 2023-08-25
CN116234831A (zh) 2023-06-06
CR20230045A (es) 2023-02-21
CO2023002334A2 (es) 2023-05-19
KR20230042292A (ko) 2023-03-28
US20230322950A1 (en) 2023-10-12
TW202221021A (zh) 2022-06-01
EP4188964A1 (en) 2023-06-07
JP2023536169A (ja) 2023-08-23
MX2023001148A (es) 2023-02-22
AU2021322054A1 (en) 2023-01-05
BR112023001740A2 (pt) 2023-02-28

Similar Documents

Publication Publication Date Title
PE20230998A1 (es) Receptores de union al antigeno mejorada
PE20081214A1 (es) Anticuerpo especifico prlr y sus usos
PE20220495A1 (es) Receptores antigenicos quimericos y agentes de union dirigidos a dll3
PE20241587A1 (es) Receptores de antigenos quimericos que se dirigen a flt3
MX2020011391A (es) Anticuerpo bcma humanizado y linfocitos t car-bcma.
EA202190607A1 (ru) Химерный антигенный рецептор для bcma на основе однодоменного антитела и его применение
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
CO6220870A2 (es) Prediccion de respuesta a un inhibidor a un inhibidor de dimerizacion her basado en expresion de her3 bajo
AR109355A2 (es) Moléculas de unión al receptor ox40 humano
WO2019241358A3 (en) Single-chain bispecific chimeric antigen receptors for the treatment of cancer
NZ765496A (en) Novel scfv amino acid sequence, chimeric antigen receptor containing same and application thereof
PE20130479A1 (es) Anticuerpos reactivos con b7-h3, fragmentos inmulogicamente activos de los mismos y usos de los mismos
MX2020010732A (es) Moleculas de union a antigeno dirigidas a her2 que comprenden 4-1bbl.
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados
PE20121361A1 (es) Antagonistas de pcsk9
RS53750B1 (en) NOTCH1 RECEPTOR BINDING AGENTS AND APPLICATION PROCEDURES
PE20050712A1 (es) Anticuerpos rg1
AR099812A1 (es) Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
CO5700152A1 (es) Nuevos anticuerpos anti-igf-ir y sus usos
CO6190543A2 (es) Anticuerpos anti-factor d humanizados
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
PE20091571A1 (es) Anticuerpos dirigidos a angiopoyetina-1 y angiopoyetina-2
ES2658224T3 (es) Anticuerpos humanizados contra receptores de tipo Toll 2 y sus usos
CL2019002953A1 (es) Anticuerpo anti-pd-l1 y uso del mismo.